To help advance clinical research on TB, GEB and the National Center for Infectious Disease Medicine at Huashan Hospital launched a research project

Study on the application value of reverse nucleic acid extraction technology in diagnosis of Mycobacterium tuberculosis in FFPE sections

On June 19,2025, the launch meeting of the project "Research on the Application Value of Reverse Nucleic Acid Extraction Technology in the Diagnosis of Mycobacterium tuberculosis in FFPE Sections", led by Huashan Hospital National Infectious Disease Medical Center and jointly undertaken by Shanghai Jinxin Biotechnology Co., LTD. (GEB), was held in the Academic Lecture Hall of the National Infectious Disease Medical Center.

This project focuses on technological innovation in the field of accurate diagnosis of Mycobacterium tuberculosis. Over 20 participants attended the meeting, including Professor Qiaoling Ruan and Dr. Yuanyuan Xu from Huashan Hospital National Center for Infectious Disease Medicine, Director ZunGuo Du from the Department of Pathology, Dr. Yu and Chief Engineer Mr.Xu from GEB, along with core members of both research teams. As the lead institution, Huashan Hospital National Center for Infectious Disease Medicine integrates clinical expertise with scientific research capabilities, while GEB leverages its core strengths in nucleic acid extraction, reaction apparatus development, and specialized equipment innovation. Together, they have established a collaborative innovation model of "clinical needs-technological R&D-translational application".

The launch ceremony was chaired by Dr. Xu Yuanyuan, who systematically outlined the project's background: Addressing industry challenges such as nucleic acid degradation and low extraction efficiency in FFPE (Frozen Sections for Pathology Examination) slide samples, this study aims to optimize the molecular diagnostic workflow for Mycobacterium tuberculosis through reverse nucleic acid extraction technology, establishing a standardized testing system to enhance pathogen detection rates and diagnostic accuracy in clinical samples. Additionally, she presented preliminary experimental data, validating the feasibility of this technology for nucleic acid preservation and efficient extraction in FFPE samples.

In their speeches, Professor Ruan Qiaoling and Director Du Zhengguo stressed that relying on the national clinical research platform of Huashan Hospital and the technological innovation capability of GEB, the two sides will carry out in-depth cooperation in sample standardization, optimization of molecular detection methodology, clinical cohort verification and other dimensions.

Dr. Yu from GEB highlighted the core advantages of reverse nucleic acid extraction technology and its groundbreaking advancements. Experts present highly praised the technology's application potential in pathologic diagnosis of infectious diseases. On behalf of GEB, Dr. Yu donated a batch of high-end laboratory consumables to Huashan Hospital to support project implementation. Dr. Yu stated that both parties will use this collaboration as a starting point to jointly establish a "Tuberculosis Mycobacterium Precision Diagnosis Technology Platform," contributing to the realization of molecular diagnostic technology popularization goals outlined in the National Tuberculosis Prevention and Control 14th Five-Year Plan.

This collaboration marks the official launch of large-scale clinical translation of reverse nucleic acid extraction technology in infectious disease pathologic diagnosis. By integrating clinical resources with innovative technologies, the project will focus on overcoming the bottleneck of efficient extraction and detection of trace pathogen nucleic acids in FFPE specimens. This breakthrough will provide novel technical tools for early tuberculosis diagnosis, drug resistance gene screening, and therapeutic efficacy monitoring.